diazoxide has been researched along with Birth Weight in 11 studies
Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.
diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.
Birth Weight: The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results of a prospective trial to evaluate the use of diazoxide and labetalol given intravenously in the management of severe hypertensive disease in pregnancy are presented." | 9.06 | Intravenous labetalol and intravenous diazoxide in severe hypertension complicating pregnancy. ( Michael, CA, 1986) |
| "Higher birth weight, diazoxide unresponsiveness and diagnosis in the first week of life were independently associated with KATP-hyperinsulinism (adjusted odds ratio: 4." | 8.02 | Birth weight and diazoxide unresponsiveness strongly predict the likelihood of congenital hyperinsulinism due to a mutation in ABCC8 or KCNJ11. ( Flanagan, SE; Hewat, TI; Houghton, JAL; Jerome, JCS; Laver, TW; Patel, KA; Shields, BM; Yau, D, 2021) |
| "The results of a prospective trial to evaluate the use of diazoxide and labetalol given intravenously in the management of severe hypertensive disease in pregnancy are presented." | 5.06 | Intravenous labetalol and intravenous diazoxide in severe hypertension complicating pregnancy. ( Michael, CA, 1986) |
| "Higher birth weight, diazoxide unresponsiveness and diagnosis in the first week of life were independently associated with KATP-hyperinsulinism (adjusted odds ratio: 4." | 4.02 | Birth weight and diazoxide unresponsiveness strongly predict the likelihood of congenital hyperinsulinism due to a mutation in ABCC8 or KCNJ11. ( Flanagan, SE; Hewat, TI; Houghton, JAL; Jerome, JCS; Laver, TW; Patel, KA; Shields, BM; Yau, D, 2021) |
| "This case series follows the evolving course of three patients with confirmed HNF4A-mediated congenital hyperinsulinism, highlighting (1) the variable natural history of these mutations, (2) the potential for prolonged diazoxide requirement, even into adolescence, and (3) the need for screening, regardless of family history." | 3.80 | The evolving course of HNF4A hyperinsulinaemic hypoglycaemia--a case series. ( Ellard, S; Flanagan, SE; Hawkes, CP; McDonnell, CM; McGlacken-Byrne, SM; Murphy, NP, 2014) |
| "These results confirm the potency of glucokinase as the pancreatic beta-cell glucose sensor, and they demonstrate that responsiveness to diazoxide varies with genotype in glucokinase hyperinsulinism resulting in hypoglycemia, which can be more difficult to control than previously believed." | 3.75 | Extremes of clinical and enzymatic phenotypes in children with hyperinsulinism caused by glucokinase activating mutations. ( Buettger, C; Chen, P; Grimsby, J; Langdon, DR; Matschinsky, FM; Odili, S; Sayed, S; Schiffman, AB; Stanley, CA; Suchi, M; Taub, R, 2009) |
| "Diazoxide was commenced in 28 patients (82." | 1.72 | Clinical and genetic heterogeneity of HNF4A/HNF1A mutations in a multicentre paediatric cohort with hyperinsulinaemic hypoglycaemia. ( Brusgaard, K; Christesen, H; Conlon, N; Dastamani, A; Demirbilek, H; Flanagan, SE; Gubaeva, D; Houghton, JAL; McGlacken-Byrne, SM; Melikyan, M; Mohammad, JK; Murphy, NP; Schou, AJ; Shah, P; Siersbæk, J, 2022) |
| "Hyperinsulinism was diagnosed as hypoglycemia concomitant with high serum insulin in babies requiring >6 mg/kg/min intravenous glucose and THI as hyperinsulinism without maternal diabetes or genetic disorders." | 1.42 | Fetal Erythroblastosis May Be an Indicator of Neonatal Transient Hyperinsulinism. ( Hata, D; Iki, Y; Katayama, T; Kawai, M; Mizumoto, H; Yamashita, S, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (36.36) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Hewat, TI | 1 |
| Yau, D | 1 |
| Jerome, JCS | 1 |
| Laver, TW | 1 |
| Houghton, JAL | 2 |
| Shields, BM | 1 |
| Flanagan, SE | 3 |
| Patel, KA | 1 |
| McGlacken-Byrne, SM | 2 |
| Mohammad, JK | 1 |
| Conlon, N | 1 |
| Gubaeva, D | 1 |
| Siersbæk, J | 1 |
| Schou, AJ | 1 |
| Demirbilek, H | 1 |
| Dastamani, A | 1 |
| Brusgaard, K | 1 |
| Melikyan, M | 1 |
| Christesen, H | 1 |
| Murphy, NP | 2 |
| Shah, P | 1 |
| Hawkes, CP | 1 |
| Ellard, S | 1 |
| McDonnell, CM | 1 |
| Yoshida, K | 1 |
| Kawai, M | 2 |
| Marumo, C | 1 |
| Kanazawa, H | 1 |
| Matsukura, T | 1 |
| Kusuda, S | 1 |
| Yorifuji, T | 1 |
| Heike, T | 1 |
| Mizumoto, H | 1 |
| Iki, Y | 1 |
| Yamashita, S | 1 |
| Katayama, T | 1 |
| Hata, D | 1 |
| Sayed, S | 1 |
| Langdon, DR | 1 |
| Odili, S | 1 |
| Chen, P | 1 |
| Buettger, C | 1 |
| Schiffman, AB | 1 |
| Suchi, M | 1 |
| Taub, R | 1 |
| Grimsby, J | 1 |
| Matschinsky, FM | 1 |
| Stanley, CA | 1 |
| Hussain, K | 1 |
| Aynsley-Green, A | 1 |
| S0vik, O | 1 |
| Vidnes, J | 1 |
| Falkmer, S | 1 |
| Michael, CA | 1 |
| Dudley, DK | 1 |
| Rosenbloom, AL | 1 |
1 trial available for diazoxide and Birth Weight
| Article | Year |
|---|---|
Intravenous labetalol and intravenous diazoxide in severe hypertension complicating pregnancy.
Topics: Adolescent; Adult; Birth Weight; Clinical Trials as Topic; Delivery, Obstetric; Diazoxide; Female; H | 1986 |
10 other studies available for diazoxide and Birth Weight
| Article | Year |
|---|---|
Birth weight and diazoxide unresponsiveness strongly predict the likelihood of congenital hyperinsulinism due to a mutation in ABCC8 or KCNJ11.
Topics: Birth Weight; Congenital Hyperinsulinism; Diazoxide; Female; Humans; Infant, Newborn; KATP Channels; | 2021 |
Clinical and genetic heterogeneity of HNF4A/HNF1A mutations in a multicentre paediatric cohort with hyperinsulinaemic hypoglycaemia.
Topics: Adolescent; Birth Weight; Child; Child, Preschool; Cohort Studies; Diabetes Mellitus, Type 1; Diabet | 2022 |
The evolving course of HNF4A hyperinsulinaemic hypoglycaemia--a case series.
Topics: Age of Onset; Antihypertensive Agents; Birth Weight; Blood Glucose; Child; Child, Preschool; Congeni | 2014 |
High prevalence of severe circulatory complications with diazoxide in premature infants.
Topics: Birth Weight; Blood Circulation; Congenital Hyperinsulinism; Diazoxide; Ductus Arteriosus, Patent; E | 2014 |
Fetal Erythroblastosis May Be an Indicator of Neonatal Transient Hyperinsulinism.
Topics: Apgar Score; Birth Weight; Diazoxide; Erythroblastosis, Fetal; Erythrocyte Count; Female; Gestationa | 2015 |
Extremes of clinical and enzymatic phenotypes in children with hyperinsulinism caused by glucokinase activating mutations.
Topics: Adolescent; Amino Acid Substitution; Birth Weight; Blood Glucose; Child; Circadian Rhythm; Diazoxide | 2009 |
Hyperinsulinaemic hypoglycaemia in preterm neonates.
Topics: Birth Weight; Chlorothiazide; Diazoxide; Diuretics; Female; Glucose; Humans; Hyperinsulinism; Hypogl | 2004 |
Persistent neonatal hypoglycaemia. A clinical and histopathological study of three cases treated with diazoxide and subtotal pancreatectomy.
Topics: Biopsy; Birth Weight; Blood Glucose; Diazoxide; Female; Follow-Up Studies; Glucose Tolerance Test; H | 1975 |
Minibolus diazoxide in the management of severe hypertension in pregnancy.
Topics: Apgar Score; Birth Weight; Diazoxide; Female; Humans; Hypertension; Infant, Newborn; Infant, Newborn | 1985 |
Ketotic (idiopathic glucagon unresponsive) hypoglycaemia: diazoxide effects.
Topics: Acidosis; Birth Weight; Blood Glucose; Child; Child, Preschool; Diazoxide; Fasting; Female; Glucagon | 1972 |